Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity.

[1]  John A. Tallarico,et al.  Abstract SY39-02: Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity , 2016 .

[2]  R. Weichselbaum,et al.  STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. , 2014, Immunity.

[3]  Ying Wang,et al.  STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. , 2014, Immunity.

[4]  T. Mitchison,et al.  Hydrolysis of 2′3′-cGAMP by ENPP1 and design of non-hydrolyzable analogs , 2014, Nature chemical biology.

[5]  Jie Zhou,et al.  STING Ligand c-di-GMP Improves Cancer Vaccination against Metastatic Breast Cancer , 2014, Cancer Immunology Research.

[6]  G. Barber,et al.  Cyclic Dinucleotides Trigger ULK1 (ATG1) Phosphorylation of STING to Prevent Sustained Innate Immune Signaling , 2013, Cell.

[7]  V. Brendel,et al.  Single Nucleotide Polymorphisms of Human STING Can Affect Innate Immune Response to Cyclic Dinucleotides , 2013, PloS one.

[8]  D. Kanne,et al.  Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants , 2013, Therapeutic advances in vaccines.

[9]  Roger A. Jones,et al.  Structure-Function Analysis of STING Activation by c[G(2′,5′)pA(3′,5′)p] and Targeting by Antiviral DMXAA , 2013, Cell.

[10]  Zhijian J. Chen,et al.  Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. , 2013, Molecular cell.

[11]  T. Mitchison,et al.  Anticancer flavonoids are mouse-selective STING agonists. , 2013, ACS chemical biology.

[12]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[13]  R. Vance,et al.  The innate immune DNA sensor cGAS produces a noncanonical cyclic dinucleotide that activates human STING. , 2013, Cell reports.

[14]  V. Hornung,et al.  cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING , 2013, Nature.

[15]  Roger A. Jones,et al.  Cyclic [G(2′,5′)pA(3′,5′)p] Is the Metazoan Second Messenger Produced by DNA-Activated Cyclic GMP-AMP Synthase , 2013, Cell.

[16]  B. Monks,et al.  Mouse, but not Human STING, Binds and Signals in Response to the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid , 2013, The Journal of Immunology.

[17]  V. Hornung,et al.  Species‐specific detection of the antiviral small‐molecule compound CMA by STING , 2013, The EMBO journal.

[18]  Yan Zheng,et al.  Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. , 2013, Current opinion in immunology.

[19]  Michael Y. Galperin,et al.  Cyclic di-GMP: the First 25 Years of a Universal Bacterial Second Messenger , 2013, Microbiology and Molecular Reviews.

[20]  Zhijian J. Chen,et al.  Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway , 2013, Science.

[21]  R. Vance,et al.  STING and the innate immune response to nucleic acids in the cytosol , 2012, Nature Immunology.

[22]  F. Marincola,et al.  Cancer classification using the Immunoscore: a worldwide task force , 2012, Journal of Translational Medicine.

[23]  S. Vogel,et al.  5,6-Dimethylxanthenone-4-acetic Acid (DMXAA) Activates Stimulator of Interferon Gene (STING)-dependent Innate Immune Pathways and Is Regulated by Mitochondrial Membrane Potential* , 2012, The Journal of Biological Chemistry.

[24]  D. Zaller,et al.  Evidence for cyclic diguanylate as a vaccine adjuvant with novel immunostimulatory activities. , 2012, Cellular immunology.

[25]  J. Wolchok,et al.  Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. , 2012, Cancer journal.

[26]  K. Murphy,et al.  Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells , 2011, The Journal of experimental medicine.

[27]  R. Schreiber,et al.  Type I interferon is selectively required by dendritic cells for immune rejection of tumors , 2011, The Journal of experimental medicine.

[28]  Yoshihiro Hayakawa,et al.  STING is a direct innate immune sensor of cyclic-di-GMP , 2011, Nature.

[29]  G. Scagliotti,et al.  Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  T. Ebensen,et al.  Bis-(3',5')-cyclic dimeric adenosine monophosphate: strong Th1/Th2/Th17 promoting mucosal adjuvant. , 2011, Vaccine.

[31]  Ivana V. Yang,et al.  Identification and Characterization of a Loss-of-Function Human MPYS Variant , 2010, Genes and Immunity.

[32]  Sky W. Brubaker,et al.  The N-Ethyl-N-Nitrosourea-Induced Goldenticket Mouse Mutant Reveals an Essential Function of Sting in the In Vivo Interferon Response to Listeria monocytogenes and Cyclic Dinucleotides , 2010, Infection and Immunity.

[33]  R. Tibshirani,et al.  In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  D. Portnoy,et al.  c-di-AMP Secreted by Intracellular Listeria monocytogenes Activates a Host Type I Interferon Response , 2010, Science.

[35]  Roger A. Jones,et al.  One-flask syntheses of c-di-GMP and the [Rp,Rp] and [Rp,Sp] thiophosphate analogues. , 2010, Organic letters.

[36]  G. Barber,et al.  STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity , 2009, Nature.

[37]  K. Ishii,et al.  A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP , 2009, The Journal of experimental medicine.

[38]  M. Tretiakova,et al.  Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. , 2009, Cancer research.

[39]  E. Unanue,et al.  Batf3 Deficiency Reveals a Critical Role for CD8α+ Dendritic Cells in Cytotoxic T Cell Immunity , 2008, Science.

[40]  Hongbin Yan,et al.  Synthesis and immunostimulatory properties of the phosphorothioate analogues of cdiGMP. , 2008, Bioorganic & medicinal chemistry letters.

[41]  G. Barber,et al.  STING an Endoplasmic Reticulum Adaptor that Facilitates Innate Immune Signaling , 2008, Nature.

[42]  F. Niesen,et al.  The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability , 2007, Nature Protocols.

[43]  G. Cheng,et al.  The vascular disrupting agent, DMXAA, directly activates dendritic cells through a MyD88-independent mechanism and generates antitumor cytotoxic T lymphocytes. , 2007, Cancer research.

[44]  T. Ebensen,et al.  The Bacterial Second Messenger cdiGMP Exhibits Promising Activity as a Mucosal Adjuvant , 2007, Clinical and Vaccine Immunology.

[45]  T. Ebensen,et al.  The bacterial second messenger cyclic diGMP exhibits potent adjuvant properties. , 2007, Vaccine.

[46]  M. Burdick,et al.  Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. , 2005, Cancer research.

[47]  Tasuku Honjo,et al.  PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells , 2004, Cancer Research.

[48]  B. Baguley,et al.  The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice , 2002, British Journal of Cancer.

[49]  Y. Kawarada,et al.  NK- and CD8+ T Cell-Mediated Eradication of Established Tumors by Peritumoral Injection of CpG-Containing Oligodeoxynucleotides1 , 2001, The Journal of Immunology.

[50]  E. Jaffee,et al.  Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. , 2000, Immunity.

[51]  B. Baguley,et al.  Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. , 1999, Cancer research.

[52]  B. Baguley,et al.  Immunomodulatory Actions of Xanthenone Anticancer Agents , 1997, BioDrugs.

[53]  W. Walker,et al.  Immortalization of cloned mouse splenic macrophages with a retrovirus containing the v-raf/mil and v-myc oncogenes. , 1988, Cellular immunology.

[54]  J. Glorioso,et al.  Engineering HSV-1 vectors for gene therapy. , 2014, Methods in molecular biology.

[55]  T. Maniatis,et al.  IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. , 2003, Nature immunology.